1057075-31-6

Basic information

• Product Name: benzylsulfonyl-(D)-Ser-Gly-4-cyanaminobenzylamide
• CAS NO: 1057075-31-6
• Molecular Weight: 445.499
• Mol File: 1057075-31-6.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: benzylsulfonyl-(D)-Ser-Gly-4-cyanaminobenzylamide(CAS DataBase Reference)
• NIST Chemistry Reference: benzylsulfonyl-(D)-Ser-Gly-4-cyanaminobenzylamide(1057075-31-6)
• EPA Substance Registry System: benzylsulfonyl-(D)-Ser-Gly-4-cyanaminobenzylamide(1057075-31-6)

Safety Data

• Hazardous Substances Data: 1057075-31-6(Hazardous Substances Data)

Upstream product

• 1939-99-7 benzenesulfonyl chloride 
• 18600-42-5 4-nitrobenzylamine hydrochloride 
• 798560-60-8 Fmoc-(D)-Ser(tBu)-Gly-4-nitrobenzylamide 
• 798560-61-9 H-(D)-Ser(tBu)-Gly-4-nitrobenzylamide 
• 798560-62-0 benzylsulfonyl-(D)-Ser(tBu)-Gly-4-nitrobenzylamide 
• 798560-63-1 benzylsulfonyl-(D)-Ser(tBu)-Gly-4-aminobenzylamide 
• 84193-63-5 H-Gly-4-nitrobenzylamide hydrochloride 
• 84193-11-3 C₁₄H₁₉N₃O₅ 
• 798560-64-2 benzylsulfonyl-(D)-Ser-Gly-4-aminobenzylamide hydrochloride 
• 506-68-3 bromocyane 

Relevant articles and documents

HYDROXYAMIDINE AND HYDROXYGUANIDINE COMPOUNDS AS UROKINASE INHIBITORS

The invention relates to novel compounds for the inhibition of the urokinase plasminogen activator (uPA) with high bioavailability and which can also be administered orally, and to the use thereof as therapeutic active ingredients for the treatment of urokinase or/and urokinase receptor associated diseases, such as, for example, tumours and metastization. The invention especially relates to compounds (I) and (II) that contain hydroxyamidine or hydroxyguanidine groups, wherein E represents a group consisting of (a).